Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer

Autor: Laura Devis‐Jauregui, August Vidal, Laura Plata‐Peña, Maria Santacana, Sandra García‐Mulero, Nuria Bonifaci, Eulàlia Noguera‐Delgado, Nuria Ruiz, Marta Gil, Eduard Dorca, Francisco J. Llobet, Laura Coll‐Iglesias, Katja Gassner, Maria Martinez‐Iniesta, Ruth Rodriguez‐Barrueco, Marc Barahona, Lola Marti, Francesc Viñals, Jordi Ponce, Rebeca Sanz‐Pamplona, Josep M. Piulats, Ana Vivancos, Xavier Matias‐Guiu, Alberto Villanueva, David Llobet‐Navas

Publikováno v: Advanced Science, Vol 10, Iss 1, Pp n/a-n/a (2023)

Abstract Clinical management of endometrial cancer (EC) is handicapped by the limited availability of second line treatments and bona fide molecular biomarkers to predict recurrence. These limitations have hampered the treatment of these patients, wh

Externí odkaz: https://doaj.org/article/88510e34e7fe4b8697754d4822ed3e67

Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer

Autor: Laura Devis‐Jauregui, August Vidal, Laura Plata‐Peña, Maria Santacana, Sandra García‐Mulero, Nuria Bonifaci, Eulàlia Noguera‐Delgado, Nuria Ruiz, Marta Gil, Eduard Dorca, Francisco J. Llobet, Laura Coll‐Iglesias, Katja Gassner, Maria Martinez‐Iniesta, Ruth Rodriguez‐Barrueco, Marc Barahona, Lola Marti, Francesc Viñals, Jordi Ponce, Rebeca Sanz‐Pamplona, Josep M. Piulats, Ana Vivancos, Xavier Matias‐Guiu, Alberto Villanueva, David Llobet‐Navas

Publikováno v: Advanced science (Weinheim, Baden-Wurttemberg, Germany).

Clinical management of endometrial cancer (EC) is handicapped by the limited availability of second line treatments and bona fide molecular biomarkers to predict recurrence. These limitations have hampered the treatment of these patients, whose survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4223fef66ac292fd7289af95c1da9e6a
https://pubmed.ncbi.nlm.nih.gov/36373729

Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

Autor: Lourdes Farre, Gabriela Sanz, Neus Ruiz-Xivillé, Manuel Castro de Moura, Juan Francisco Martin-Tejera, Samuel Gonçalves-Ribeiro, Maria Martinez-Iniesta, Monica Calaf, Jose Luis Mosquera, José Ignacio Martín-Subero, Isabel Granada, Manel Esteller, Eva Domingo-Domenech, Fina Climent, Alberto Villanueva, Anna Sureda

Publikováno v: Disease Models & Mechanisms
article-version (VoR) Version of Record
Dipòsit Digital de la UB
Universidad de Barcelona
Disease Models & Mechanisms, Vol 14, Iss 7 (2021)

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bbde2d5324a2db66a5aa617fcc12d0a4
https://pubmed.ncbi.nlm.nih.gov/33988237